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Abstract
Background: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of
psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not
usually met with conventional systemics. Nevertheless, some patients continue to experience persistent disease
activity or treatment failure over time. Strategies to optimize treatment outcomes include the use of concomitant
methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment efficacy in psoriasis
and other inflammatory diseases.
Methods: This is an investigator-initiated, multicenter randomized controlled trial (RCT) designed to compare the
combination treatment of adalimumab and methotrexate with adalimumab monotherapy in patients with psoriasis.
The primary outcome is adalimumab drug survival at week 49. Other outcomes include improvement in disease
severity and quality of life, tolerability, and safety. Moreover, anti-adalimumab antibodies and adalimumab serum
concentrations will be measured and correlations between genotypes and clinical outcomes will be assessed.
Patient recruitment started in March 2014. Up to now, 36 patients have been randomized. Many more patients
have been (pre)screened. A total of 93 patients is desired to meet an adequate sample size. In our experience,
the main limitation for recruitment is prior adalimumab therapy and intolerability or toxicity for methotrexate in
the past.
Discussion: OPTIMAP is the first RCT to examine combination therapy with adalimumab and methotrexate in a
psoriasis population. With data derived from this study we expect to provide valuable clinical data on long-term
treatment outcomes. These data will be supported by assessment of the impact of concomitant methotrexate on
adalimumab pharmacokinetics. Furthermore, the influence of several single nucleotide polymorphisms on
adalimumab response will be analyzed in order to support the development of a more personalized approach for
this targeted therapy.
Trial registration: NTR4499. Registered on 7 April 2014.
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Background
Adalimumab has been shown to be highly valued by pa-
tients with psoriasis due to its profound improvements in
disease severity and its favorable safety profile [1, 2]. Al-
though its introduction (together with other anti-tumor
necrosis factor (TNF) medications) has majorly advanced
psoriasis care, some patients experience persistent disease
activity (primary non-responders), treatment failure over
time (secondary non-responders), or side effects [3–5].
Several factors have been identified to play a role in pri-
mary and secondary non-response to anti-TNFs, including
pharmacokinetic factors such as the formation of anti-
drug antibodies (immunogenicity) and inter-individual
variation in serum drug concentrations as well as pharma-
cogenetic factors such as the absence or presence of cer-
tain single nucleotide polymorphisms (SNPs) affecting
drug metabolization [6, 7].
When anti-drug antibodies are formed in patients
treated with an anti-TNFα, clearance of the biologic can,
to a certain extent, be accelerated depending on the con-
centration of the anti-drug antibodies [8]. Moreover,
anti-drug antibodies can be functionally neutralizing,
thereby directly affecting treatment efficacy [9]. Multiple
studies observed an association between the formation
of anti-adalimumab antibodies, reduced serum levels,
and diminished clinical response in psoriasis and other
chronic inflammatory diseases [3, 10–13]. In rheumatoid
arthritis (RA) and Crohn's disease, concomitant use of
methotrexate (MTX) during treatment with certain
TNFα inhibitors (adalimumab, infliximab, and golimu-
mab) has been demonstrated to decrease immunogen-
icity and significantly reduce clearance, resulting in
higher systemic exposure and enhanced clinical efficacy
[11, 14–18]. Therefore, the use of combination therapy
may be beneficial for successful long-term adalimumab
treatment. In addition, combination therapy may enable
dose reductions of individual agents, thereby decreas-
ing toxicity and improving tolerability and compliance
[19]. By targeting unregulated increased cytokine
levels associated with inflammatory comorbid condi-
tions, it is hypothesized that combination therapy
may also provide a broader benefit to the patient by
reducing the risk of, for example, cardiovascular
events [20].
On the other hand, combination therapy may theoret-
ically convey an increased risk for serious infections and
malignancies.
Currently available evidence on anti-TNFα therapy
with MTX in psoriasis is limited to two randomized
controlled trials (RCTs) on etanercept with MTX [19, 21, 22]
and a few observational studies and case series on
other different anti-TNFα agents with MTX [23–25].
The two RCTs on etanercept and MTX provided
promising results with superior efficacy of etanercept
with MTX compared to etanercept monotherapy.
RCTs investigating combined treatment with adalimu-
mab and MTX are lacking [19, 26].
In order to investigate whether adalimumab treatment
can be optimized by using concomitant MTX, long-term
clinical and pharmacokinetic data on the use of adalimu-
mab in combination with MTX are desired. Additionally,
as several polymorphisms have been identified as
potential predictors for anti-TNF therapy in psoriasis (e.g.,
TNFR1B, TNFAIP3, IL12B/IL23R) [6, 27] and other
chronic inflammatory diseases (e.g., FcGR and ATG16L1)
[28, 29], it will be valuable to detect genetic factors associ-
ated with response to adalimumab in order to support
personalized care.
Aims and objectives
The aims and objectives of this trial are:
– To gain long-term RCT data on the efficacy and
safety of adalimumab combined with MTX
compared to adalimumab monotherapy
– To assess the impact of concomitant MTX on
adalimumab immunogenicity and serum
concentrations
– To test appropriate candidate genes and correlate
genotypes with trial outcomes
Methods
This is a multicenter RCT reported according to the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (see Table 1 (SPIRIT
table) and Additional file 1 (SPIRIT checklist)). The trial
was granted ethics approval by the Academic Medical
Center research ethics committee (METC 2013_346).
The trial is registered at The Netherlands National Trial
Register (trial number: NTR4499) and in the European
Clinical Trials Database (EudraCT number: 2013-
004918-18). All participants will sign informed consent
before participation. The study is being conducted ac-
cording to the principles of the Declaration of Helsinki
and in accordance with the Medical Research Involving
Human Subjects Act (WMO) and other relevant guide-
lines, regulations, and acts.
Participants
Patients will be recruited from the outpatient clinics of
the Departments of Dermatology of the Academic
Medical Center (AMC) Amsterdam, Erasmus University
Medical Center (EMC) Rotterdam, and the Radboud
University Medical Center (RUMC) Nijmegen. More-
over, other dermatologists will be contacted to recruit
and refer eligible patients to the participating centers.
Participants must meet the inclusion criteria and none
of the exclusion criteria (Table 2) in order to participate.
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These criteria will be assessed at the screening visit.
Potential participants who are deemed ineligible at
screening will be allowed a second screening visit if the
reason for ineligibility is a temporary status (e.g., latent
tuberculosis).
Interventions
All patients receive adalimumab 40 mg subcutaneously
every other week starting 1 week after a loading dose of
80 mg and will be randomized 1:1 to receive either oral
MTX 10 mg weekly (combination group) or no addition
of MTX (monotherapy group). MTX therapy will be
initiated 2 weeks prior to adalimumab therapy, and
administration will be followed by folic acid 5 mg
24 hours after MTX intake (see Table 1).
In case of MTX toxicity (e.g., liver toxicity or
leukopenia) or intolerability, dosing can be paused
(for a maximum of 2 weeks up to four times during
the entire study), or the dose can be adjusted to
7.5 mg. Moreover, patients are allowed to switch from
oral to subcutaneous administration. In case of adali-
mumab toxicity or intolerability, dosing can be paused
(for a maximum of 2 weeks up to four times during
the entire study).
Throughout the study, no systemic anti-psoriatic drugs
are allowed for treatment other than the study medication
(Table 3). If medically necessary (i.e., to control intolerable
psoriasis activity), rescue treatment with topical cortico-
steroids, vitamin D derivates (calcipotriol/betamethasone
Table 1 Timeline of the study according to the SPIRIT guidelines
Time Screening Week
−2
Week
−1
Week
0
Week
3
Week
5
Every 12 weeks
from week 13
up to week 145
Early
termination
Enrollment
Informed consent X
Demography, medical history X
Vital signs and full physical examination X X X X X
Psoriasis Area and Severity Index (PASI) X X X X X
Eligibility criteria X
Laboratory assessments X X X X X X X
Chest X-ray, Mantoux test, and interferon-gamma release
assay (IGRA)
X
Randomization X
Intervention
Adalimumab (Humira) + MTX X (MTX) X (MTX) X (Humira + MTX)
Humira monotherapy X (Humira)
Assessments
Laboratory assessments X X X X X X X
PASI X X X X X
Physician global assessment X X X X X
Patient global assessment X X X X X
Impact on quality of life (Skindex 29 and Dermatology Life
Quality Index (DLQI))
X X X X X
Prior or concomitant therapy X X X X X
Adverse events X X X X X
Drug adherence X X X X
Table 2 Eligibility criteria
Inclusion Exclusion
≥18 years
Diagnosis of moderate to severe
plaque psoriasis (PASI ≥8)
Adalimumab naïve
Candidate for biologic therapy
Willing and able to use adequate
contraceptives during the study
History of significant MTX toxicity,
intolerability, or contraindication
Known liver or kidney malfunction
Alcohol abuse
Bone marrow hypoplasia,
leukocytopenia, thrombocytopenia,
or significant anemia
Known severe or chronic infections
like tuberculosis or HIV
Ulcers in the oral cavity or known
active ulcers in digestive tract
Pregnant or nursing women
Need for live vaccinations
Use of other immunosuppressive
medication (e.g., prednisone,
mycophenolate mofetil (Cellcept),
cyclosporine (Neoral), sirolimus
(Rapamune), systemic tacrolimus
(Prograf))
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or calcitriol), or calcineurin inhibitors may be provided to
study patients at the discretion of the investigator after
baseline and through week 145 (end of study) (Table 4).
Randomization and blinding
Consecutive patients will be prospectively enrolled and
randomly assigned if eligible to either the intervention
(adalimumab with MTX) or control (adalimumab mono-
therapy) group after obtaining informed consent. Each
consecutive patient will be assigned a randomization
number according to a computer-generated randomization
list (ALEA) using random block sizes of 2, 4, 6, and 8 to en-
sure allocation concealment. Randomization is stratified for
TNFα-blocker exposure status to achieve balance with regard
to prior TNFα-blocker exposure in the study population.
This is an observer-blinded study. The observer (out-
come assessor) will perform clinical outcome assessments
of disease severity (Psoriasis Area and Severity Index
(PASI) and investigator global assessment (IGA)) at each
study visit. The clinician performs all other study proce-
dures and is not blinded. Both clinician and participant
know the treatment allocation; as such, no special mea-
sures are required to allow for breaking of treatment
codes. However, treatment allocation will not be revealed
to the recruiting physician until participants’ details and
key stratification variables have been irrevocably entered
onto the web-based randomization site.
Endpoints
The primary outcome is adalimumab drug survival
(number of patients still on adalimumab treatment) at
week 49.
Secondary outcomes are the following:
 Adalimumab drug survival (number of patients still
on adalimumab treatment) at week 145
 Proportion of patients who reach treatment goals1 at
week 13, week 25, week 49, and week 145
 Proportion of patients achieving PASI 75 at weeks
49 and 145
 Proportion of patients achieving IGA clear or almost
clear at weeks 49 and 145
 Mean improvement in PASI at weeks 49 and 145
 Proportion of patients with PGA clear or almost
clear at weeks 49 and 145
 Mean improvement in Dermatology Life Quality
Index (DLQI) and Skindex at weeks 49 and 145
 Proportion of patients with (serious) adverse events
at weeks 49 and 145
 Proportion of patients with changes in laboratory
assessments at weeks 49 and 145
 Proportion of patients with (no, low, or high) levels
of antibodies at weeks 49 and 145
 Median adalimumab trough concentrations (mg/L)
at weeks 49 and 145
 Correlation between genetic polymorphisms and
adalimumab response
Procedures and assessments
Patients will visit the outpatient clinic at screening, base-
line, week 5, week 13, and every 12 weeks thereafter
until study completion (weeks 25, 37, 49, 61, 73, 85, 97,
109, 121, 133, 145) (Table 1). A variety of parameters
will be collected during each visit to assess efficacy, in-
cluding physician- (PASI/IGA (static; scale 0–4 [30]))
and patient-reported (patient-reported global assessment
(PGA static; scale 0–4)) outcomes. Quality of life assess-
ment will be performed using Skindex and DLQI ques-
tionnaires. Safety will be assessed by evaluating the
incidence of (serious) adverse events, obtaining a de-
tailed medical history, thorough physical examination,
vital signs, clinical laboratory testing, and urinalysis (in-
cluding pregnancy tests for females of childbearing po-
tential at screening). Concomitant medication and
medical procedures will be collected from obtainment of
informed consent up to end of study. Patients will re-
ceive a diary in which they will register the administra-
tion dates of adalimumab (and MTX in the combination
group), any changes in their health status, and/or
changes in concomitant medication used. The local in-
vestigator reviews the diary to determine drug adherence
and the incidence and type of adverse events. An inde-
pendent Data Safety Monitoring Board (DSMB) has
been established to review efficacy and safety data peri-
odically in an unblinded fashion.
Laboratory testing
Blood samples will be collected at each visit (serum
samples are collected just before administration of
adalimumab (3-day window) to ensure accurate deter-
mination of serum through levels) to monitor drug safety,
to determine immunogenicity against adalimumab, and to
Table 3 Wash-out periods
Therapy Wash-out period
Topical therapy 2 weeks
Phototherapy 2 weeks
Conventional systemic therapy/etanercept 4 weeks
Infliximab/ustekinumab 6 weeks
Table 4 Allowed escape medication
Scalp/palms/
soles
Low or high potency corticosteroids, calcitriol/
calcipotriol, or a combination
Face and
body
Low potency corticosteroids, calcitriol/calcipotriol, or
topical tacrolimus 0.1% or 0.03%
inverse
psoriasis
Topical tacrolimus 0.1% or 0.03%
Busard et al. Trials  (2017) 18:52 Page 4 of 8
measure adalimumab serum through levels. Samples for
serum preparation are kept at room temperature for 1–2
hours for coagulation, followed by centrifugation at 3000
RPM for 15 minutes at room temperature. Supernatant is
collected, aliquoted, and stored at −20 °C until further use.
Adalimumab serum through levels will be determined
using a non-commercial enzyme-linked immunosorbent
assay (ELISA, Sanquin, Amsterdam, The Netherlands).
Detection of anti-adalimumab antibodies will be per-
formed through a radioimmunoassay (Sanquin). The anti-
body test will be considered positive when the antibody
concentration exceeds 12 AU/mL. Concentrations be-
tween 12 and 100 AU/mL will be considered low antibody
titers; those above 100 AU/mL will be considered high
antibody titers [3].
Additionally, a single blood sample will be collected at
screening from which DNA will be collected and stored
at −80 °C. As scientific interest in this field is currently
increasing, DNA analysis will be performed based upon
accumulating data acquired from (ongoing) pharmaco-
genetic studies.
Justification of sample size
A total of 84 patients (randomized 1:1 to concomitant
MTX or no MTX) will give the study at least 80% power
at a 0.05 two-sided significance level using a two-sample
chi-squared test to detect a difference of 28% in drug
survival at week 49. We aim to enroll 93 patients to
allow for an approximate 10% loss to follow-up. These
calculations were performed using Nquery 6.0.2. Due to
the lack of data in a psoriasis population, the expected
clinically relevant difference in drug survival between
both treatment groups was hypothesized based on stud-
ies performed in patients with RA. The prevalence of
(clinically relevant) anti-drug antibody formation is esti-
mated to be 45% in patients on adalimumab monother-
apy (a similar percentage is found in patients with
psoriasis [31] and around 17% in patients on adalimu-
mab with low-dose (5–10 mg) MTX after 49 weeks [32].
A clear correlation between antibody formation and
treatment failure (with subsequent treatment discontinu-
ation) in patients on adalimumab has been demonstrated
[31]. Based on these data, drug survival is estimated to
be 83% (100 minus 17) for the experimental group and
55% (100 minus 45) for the control group after 49 weeks
of follow-up.
Statistical analysis
The primary analysis will be conducted on the
intention-to-treat population, including all randomized
participants in the groups to which they were ran-
domized. A per-protocol population (excluding major
protocol violations) will be used to check the robust-
ness of the primary analyses. The safety population
will consist of all patients receiving at least one dose
of the study drug.
Adverse events will be coded according to the Medical
Dictionary for Regulatory Activities (MedDRA) adverse
event classification. The overall incidence of (serious)
adverse events and number and proportion of patients
reporting such events will be summarized by treatment
group.
Differences in dichotomous outcomes among the
two study groups will be analyzed using the chi-
squared test or Fisher’s exact test when the expected
cell frequencies fall below 5. We will express differ-
ences in drug survival as absolute differences and
relative risks, with associated 95% confidence inter-
vals, with the group on adalimumab monotherapy as
the reference. In case patients are lost to follow-up
during the study period, we will analyze these data by
means of survival analysis. We will construct cumula-
tive survival curves (Kaplan-Meier method) for the
treatment groups, and these curves will be compared
using the log-rank test. One-way analysis-of-variance
statistics will be calculated to compare continuous
outcome measures between groups.
There are no formal planned interim analyses, but
progress reports on all data issues are presented to the
DSMB.
Trial status
Patient recruitment started in March 2014 and is cur-
rently ongoing. Based on our experience so far, recruit-
ment is limited by two main factors: prior use of
adalimumab and intolerability or toxicity for MTX in
the past.
Moreover, disease activity in patients who are transi-
tioned from another biologic is often suppressed (<PASI
8). To enlarge the geographical area in which patients
can participate in the study and to enhance patient re-
cruitment, three additional hospitals have been activated
for patient recruitment: Amphia Hospital (Breda) and
Bravis Hospital (Bergen op Zoom) in The Netherlands
and Ghent University Hospital in Belgium.
Discussion
Although combination treatment with anti-TNFs and
MTX is being prescribed for psoriasis in clinical prac-
tice, available evidence and guidance on the use of com-
bination treatment is limited. No consensus about
certain treatment aspects such as timing of initiation of
MTX (prior to anti-TNF or during anti-TNF therapy)
and MTX dosing exists. Therefore, besides the rationale
for our primary endpoints, we would like to emphasize
the choice of dosing and initiation of comedication for
the current RCT.
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Primary endpoint
In this study, drug survival after 49 weeks of treatment
is chosen as the primary endpoint. Based on currently
available evidence, response rates to anti-TNFs in pa-
tients with and without concomitant MTX may remain
similar; however, drug survival is often superior in pa-
tients receiving comedication compared to monother-
apy, and this difference tends to be more prominent
than differences in response rates [33–36]. Moreover, by
categorizing reasons for treatment discontinuation (lack
of efficacy, safety concerns), several important treatment
aspects are being combined.
Initiation of MTX prior to adalimumab therapy
Concomitant use of MTX has been demonstrated to sig-
nificantly reduce the clearance of adalimumab, resulting
in higher adalimumab trough levels in patients with RA
[14, 37]. However, it takes time for MTX to exert a full ef-
fect on the pharmacokinetics of adalimumab [37]. The
slow onset of drug action of MTX can be attributed to an
intracellular accumulation process [38, 39]. After MTX
uptake into cells, it is converted to MTX polyglutamates,
active metabolites which are believed to exert the anti-
inflammatory actions of MTX. The current product label
for adalimumab indicates that MTX decreases the appar-
ent clearance of adalimumab after single and multiple
doses by 29% and 44%, respectively [37].
In order to ensure maximal potential for MTX to exert
a beneficial effect on adalimumab pharmacokinetics
from the start on, MTX therapy is initiated 2 weeks
before administration of adalimumab in the intervention
group.
Choice of MTX dosing
The dose of MTX as monotherapy can range from 7.5
to 25 mg/week, depending on national guidelines and
patient/physician’s preference. A systematic literature re-
view of MTX monotherapy has recommended initial
treatment with 10–15 mg orally with dose increases to
20 mg/week if needed and tolerated [40]. Available evi-
dence suggests that MTX toxicity is dose-dependent and
low-dose MTX monotherapy treatment can be effective.
However, no RCTs have explored the minimally effective
dose of MTX in a group of patients when used in
combination with a TNFα inhibitor. This dose may differ
from minimally effective monotherapy doses.
MTX tends to reduce immunogenicity and increase
adalimumab serum levels in a dose-dependent manner
in patients with RA. Results indicate a (non-significant)
increase in adalimumab serum concentrations with
higher doses of MTX (10–20 mg) compared to low-dose
MTX. However, a dose of 5–10 mg of concomitant
MTX seems already sufficient to substantially decrease
immunogenicity against adalimumab and maintain
serum concentrations within the therapeutic range [32,
41]. In the treatment of psoriasis, MTX 10 mg per week
is an accepted dose for treating psoriasis according to
(inter)national guidelines [40]. In order to avoid an in-
creased risk of side effects like hepatotoxicity, a dosage
of 10 mg MTX/week is chosen in our RCT over a higher
dose.
With this RCT we aim to improve the body of evi-
dence on efficacy and safety of adalimumab and MTX
combination treatment in order to investigate whether
MTX can optimize adalimumab treatment. Moreover,
with the analysis of pharmacogenetic data, we hope to
support personalized medicine and more accurate pre-
diction of treatment response.
Study strengths and limitations
This study represents the first RCT on combined treat-
ment with adalimumab and methotrexate. Data will be
extracted and analyzed independent of industry. It is an
observer-blinded study with concealment of allocation.
Clinical as well as pharmacokinetic and pharmacoge-
netic outcomes will be assessed in the short and long
term.
However, some limitations apply. Due to the pragmatic
study design, the trial is not conducted as double-blind.
Moreover, the sample size limits assessment of the pre-
dictive performance of genetic polymorphisms on clin-
ical and pharmacokinetic outcomes. Optimal dosing and
timing of MTX comedication are not evaluated in this
study and will have to be investigated in future research.
Endnotes
1Treatment goals will be achieved if patients reach
PASI ≥ 75 or PASI ≥ 50 in combination with DLQI ≤ 5.
Treatment goals will not be achieved if PASI < 50 or
PASI ≥50 < 75 in combination with DLQI ≥ 5 [42].
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents.* (DOC 121 kb)
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